GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (FRA:0KB2) » Definitions » Valuation Rank

Humanigen (FRA:0KB2) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Humanigen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Humanigen Valuation Rank Related Terms

Thank you for viewing the detailed overview of Humanigen's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Humanigen (FRA:0KB2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (FRA:0KB2) » Definitions » Valuation Rank
Comparable Companies
MYMX RSPI RBSH KRBP CNBX EVFM PPCB CALA QBIO RGMP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HGENQ:USA
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Website
https://www.humanigen.com
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.